Cristiane Pereira Vargas Cousseau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristiane Pereira Vargas Cousseau has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Laus
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
1 shared publication - André Lopes Carvalho
Early Detection, Prevention & Infections Branch International Agency for Research on Cancer Lyon France
1 shared publication - Bruna Pereira Sorroche
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1 shared publication - Lidia Maria Rebolho Batista Arantes
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil
1 shared publication - Luciane Sussuchi da Silva
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1 shared publication - Matias Eliseo Melendez
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1 shared publication
Latest Publications
- 31 July 2023
- Published by Wiley in Head & Neck
- Vol. 45 (10) , 2489-2497
miR‐99a‐5p as a biomarker for lymph node metastasis prediction in oral squamous cell carcinoma patients
Background: Metastatic lymph node involvement influences therapy decisions and serves as a prognostic indicator in oral squamous cell carcinoma (OSCC). However, many early‐stage patients with clinically negative lymph nodes exhibit no metastasis upon surgical staging. This study aimed to identify differentially expressed miRNAs capable of distinguishing pathologically positive (pN+) from negative (pN0) nodes in OSCC patients without clinical evidence of lymph node metastases (cN0).Methods: Expression levels of 798 miRNAs were assessed in tumor samples from 10 pN+ and 10 pN0 patients using the Nanostring nCounter platform. Validation was performed in an independent cohort of 15 pN+ and 24 pN0 patients through RT‐qPCR.Results: Eight miRNAs exhibited differential expression between pN0 and pN+ patients. Notably, hsa‐miR‐99a‐5p demonstrated high sensitivity and specificity in predicting patients at higher risk of positive lymph nodes.Conclusions: These findings highlight hsa‐miR‐99a‐5p as a potential biomarker for detecting lymph node metastasis in primary OSCC tumors.
- 31 July 2023
- Published by Wiley in Head & Neck
- Vol. 45 (10) , 2489-2497
miR‐99a‐5p as a biomarker for lymph node metastasis prediction in oral squamous cell carcinoma patients
Background: Metastatic lymph node involvement influences therapy decisions and serves as a prognostic indicator in oral squamous cell carcinoma (OSCC). However, many early‐stage patients with clinically negative lymph nodes exhibit no metastasis upon surgical staging. This study aimed to identify differentially expressed miRNAs capable of distinguishing pathologically positive (pN+) from negative (pN0) nodes in OSCC patients without clinical evidence of lymph node metastases (cN0).Methods: Expression levels of 798 miRNAs were assessed in tumor samples from 10 pN+ and 10 pN0 patients using the Nanostring nCounter platform. Validation was performed in an independent cohort of 15 pN+ and 24 pN0 patients through RT‐qPCR.Results: Eight miRNAs exhibited differential expression between pN0 and pN+ patients. Notably, hsa‐miR‐99a‐5p demonstrated high sensitivity and specificity in predicting patients at higher risk of positive lymph nodes.Conclusions: These findings highlight hsa‐miR‐99a‐5p as a potential biomarker for detecting lymph node metastasis in primary OSCC tumors.